Astellas Pharma Global Development, Inc.

This study tests a combination of two drugs, enfortumab vedotin and pembrolizumab, in people with muscle-invasive bladder cancer. The goal is to see if this treatment can eliminate the cancer and allow patients to keep their bladder instead of having it surgically removed. The st…

This early-stage study tests a new drug called ASP1002 in about 210 adults whose solid tumors have spread or can't be removed. The drug targets tumors with high levels of a protein called claudin 4. The main goals are to check safety, find the best dose, and see if the drug can c…

This study tests a new medicine called PRL-02 depot, given as a shot into the muscle every 12 weeks, to lower testosterone in men with advanced prostate cancer. The goal is to find a safe dose and see if it works alone or with another drug, enzalutamide. About 174 men whose cance…

This early-stage study tests a new drug called ASP2998, which targets a protein (TROP2) found on many solid tumors. The drug is given alone or with standard treatments like pembrolizumab or carboplatin. About 428 adults with advanced bladder, lung, stomach, or breast cancers that…

This study looks at the long-term safety of enzalutamide, a drug for prostate cancer. It is for people who have already been helped by enzalutamide in a previous study. About 900 participants will continue their treatment and be monitored for side effects.

This early-phase study tests a new drug, ASP2138, that helps the immune system find and attack cancer cells that have a specific marker called CLDN18.2. The study includes adults with advanced stomach, gastroesophageal junction, or pancreatic cancer that cannot be removed by surg…

This early-stage study tests a new drug called ASP5541 in about 12 Chinese men with advanced prostate cancer. The drug is given as a shot in the hip, along with standard treatments (prednisone and hormone therapy). The main goals are to see if the drug is safe and how it is proce…

This study tests whether a combination of two drugs (enfortumab vedotin and pembrolizumab) can control muscle-invasive bladder cancer and allow patients to keep their bladder. About 390 adults whose cancer hasn't spread outside the bladder and who cannot or choose not to have bla…

This early-stage study tests the drug gilteritinib in about 40 adults with advanced ALK-positive non-small cell lung cancer whose cancer no longer responds to standard ALK inhibitors. Gilteritinib is already approved for a type of leukemia and may also block faulty ALK signals. T…

This study tests a new drug called ASP546C in people with advanced stomach, gastroesophageal junction, pancreatic, or other solid tumors that have a specific marker (CLDN18.2). The trial has two parts: Part 1 finds the best dose in stomach/GEJ cancer patients, and Part 2 tests th…

This study tests an oral medicine called roxadustat for anemia in children and teenagers with chronic kidney disease. Anemia means low red blood cells, which can cause tiredness and weakness. The medicine is already approved for adults and is taken three times a week for up to a …

This study tests a new drug called ASP2138 in people with a type of pancreatic cancer that can be removed by surgery. The drug helps the immune system attack cancer cells that have a specific protein (CLDN18.2). Participants receive ASP2132 two weeks before surgery, then standard…

This program provides early access to zolbetuximab, a drug that targets a protein called claudin18.2 found on some stomach cancer cells. It is for people with advanced stomach or gastroesophageal junction cancer that has not been treated yet. Participants receive zolbetuximab plu…

This study tests whether adding the experimental drug setidegrasib to standard chemotherapy helps people with a specific genetic form of advanced pancreatic cancer (KRAS G12D mutation) live longer. About 614 adults whose cancer has spread and cannot be removed by surgery will rec…

This study tests a new injectable form of the hormone therapy abiraterone (ASP5541) in men with advanced prostate cancer that has spread. The shot is given every 12 weeks, instead of daily pills. The goal is to see if it works as well as or better than the standard pill, and to c…

This study is for Indian adults with advanced or metastatic urothelial cancer (bladder cancer that has spread). The main goal is to confirm the safety of the drug enfortumab vedotin. Participants will receive the drug through an IV infusion every 28 days. The study will monitor f…

This study tests whether adding zolbetuximab to standard immunotherapy (pembrolizumab) and chemotherapy helps people with advanced stomach or gastroesophageal junction cancer live longer. The trial enrolls 500 adults whose tumors have specific proteins (CLDN18.2 and PD-L1) but la…

This study follows children (over 6) and adults with Stargardt disease or similar inherited eye conditions to see how their vision changes over 2 years. Participants get standard eye tests every 6 months, but no new treatment is given. The goal is to better understand how these d…

This study follows 1,000 people with geographic atrophy (an advanced form of age-related macular degeneration) who are already starting treatment with the drug Izervay. Researchers will collect information from medical records and surveys over up to 5 years to see how the drug is…

This study looks at how three common medicines (fluconazole, itraconazole, and carbamazepine) change the way the body processes an experimental cancer drug called ASP3082. About 54 healthy adults will take ASP3082 alone and with each of the other drugs to measure differences in d…